List view / Grid view
15 September 2014 | By Abbott
Abbott announced positive one-year clinical results from ABSORB II, the world's first prospective, randomized, controlled trial comparing the safety and effectiveness of the dissolving Absorb heart device to Abbott's market-leading metallic XIENCE family of DES...
15 September 2014 | By Roche
Roche announced that phase III clinical studies have been initiated for lampalizumab, an investigational drug for geographic atrophy, the advanced form of age-related macular degeneration, a progressive condition which can result in blindness...
15 September 2014 | By Issued on behalf of the IHMA by MHW PR Ltd
Millions of fakes pouring into EU, US and Japanese markets...
12 September 2014 | By Eli Lilly and Company
Eli Lilly and Company announced that the RAISE trial, a Phase III study of ramucirumab (CYRAMZA™) in combination with chemotherapy in patients with metastatic colorectal cancer (mCRC), met its primary endpoint of overall survival...
12 September 2014 | By Tiziana Life Sciences
Tiziana Life Sciences announces the appointment of Professor Roberto Pellicciari to the Company’s Scientific Advisory Board and as a consultant to the Company...
12 September 2014 | By Abbott
Abbott's board of directors has approved a new share repurchase program and declared a quarterly common dividend...
12 September 2014 | By Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. announced its participation in the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place in Vienna September 15-19...
12 September 2014 | By Rigaku
Rigaku Raman Technologies, a leading pioneer of handheld and portable Raman spectrometers, will be showcasing its new generation handheld Raman analyzer for raw material identification (RMID) in booth 1C82 at CPhI Worldwide 2014...
11 September 2014 | By Advanced Accelerator Applications and GE Healthcare
Advanced Accelerator Applications strengthens its position in the Italian PET Radiopharmaceutical Market...
11 September 2014 | By Waters
Waters Corporation celebrated the official opening of its new, custom-built mass spectrometry headquarters in Wilmslow, UK, confirming the company's commitment to innovation and the expanded usage of mass spectrometry...
11 September 2014 | By Futura Medical plc
Futura Medical plc is pleased to announce its interim results for the six months ended 30 June 2014...
10 September 2014 | By Boehringer Ingelheim
The European Commission granted marketing authorisation for Eli Lilly and Company and Boehringer Ingelheim’s insulin glargine product, indicated to treat diabetes in adults, adolescents and children aged 2 years and above...
10 September 2014 | By GlaxoSmithKline
GSK announced a £5m collaboration with the UK and South African Medical Research Councils, to support much-needed research into non-communicable diseases in Africa, as part of GSK’s Africa NCD Open Lab initiative...
10 September 2014 | By Novartis
Novartis announced that new data presented at the Joint ACTRIMS-ECTRIMS Meeting in Boston, USA, reinforces the clinical importance of measuring brain shrinkage (brain volume loss) in multiple sclerosis...
10 September 2014 | By Actavis
Actavis plc confirmed that the U.S. Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee has voted to recommend against approval of Actavis' New Drug Application for the fixed-dose combination of nebivolol and valsartan for the treatment of hypertension...
